Download PHS 398/2590, Other Support Format Page

Principal Investigator: James S. Economou
(Last, first, middle)
PHS 398/2590 OTHER SUPPORT
ECONOMOU, J.S.
ACTIVE
R01 CA 79976 (Economou)
01/01/03-01/31/08
NIH/NCI
$1,308,809
Dendritic cell-based genetic immunotherapy for melanoma.
Role: Principal Investigator
1.2 calendar months
1 R01 CA129816-01 (Economou)
07/01/07-06/30/12
NIH/NCI
$1,250,000
PET imaging of MART TCR-engineered CD8 T cells immunotherapy in man.
Role: Principal Investigator (with Antoni Ribas as Co-PI)
2.4 calendar months
W M Keck Foundation (Economou)
Genetic Engineering of the Human Immune System.
Role: Principal Investigator
1.2 calendar months
07/01/07-06/30/10
$1,800,000
20061804 (Economou)
07/01/06-06/30/08
.60 calendar months
Samuel Waxman Cancer Research Fund
$600,000
The UCLA-Caltech-USC Children’s Hospital-UConn Engineered Immunity Consortium of TCR-Engineered
Immunity Consortium of TCR-Engineered Lymphocytes for In Vivo Targeting and Treatment of Human
Melanoma.
Role: Principal Investigator
K12 CA76905 (Economou)
NIH/NCI
Clinical Scientist Training in Cancer Gene Medicine.
Role: Principal Investigator
07/01/97-6/30/08
$2,319,760
1.2 calendar months
National Gene Vector Laboratories (Economou)
NIH
Treatment and biological imaging of patients with locally advanced or metastatic melanoma with lentiviral
vector MART-1 TCR/HSV1-sr39tk (FUW-M1-TCR/sr39tk) engineered lymphocytes MART-1 pulsed
dendritic cells, and interleukin-2 after a nonmyeloablative conditioning regimen (for construction of a clinical
grade lentiviral vector).
National Institutes of Health Rapid Access to Interventional Development
RAID Project No. 176: “A Phase I/II Trial Testing Immunization with AFP Plasmid Prime and AFP
Adenoviral Vector Boost in Patients with Hepatocellular Carcinoma.”
Total Award: cost of GMP manufacture > $1 million (2003-2007)
P30 CA016042 (Gasson)
NIH/NCI
UCLA-Jonsson Comprehensive Cancer Center
Cancer Center Support Grant
Role: Deputy Director
PHS 398/2590 (Rev. 09/06)
12/1/02 -11/30/08
$3,067,154
Page _____
2.4 calendar months
Other Support Format Page
Principal Investigator: James S. Economou
(Last, first, middle)
R01 CA104524 (Butterfield)
2007-2010
NIH/NCI
$750,000
Title: AFP-based prime boost immunotherapy for hepatocellular cancer
Role: Co-Principal Investigator
.24 calendar months
P50 CA 086306 (Herschman)
05/01/05- 04/30/10
NIH/NCI
$1,274,299
Title: The UCLA Center for In Vivo Imaging in Cancer Biology.
Project I. In vivo imaging of antigen-specific T cells in mice and humans.
Role: Co-Investigator (with Ribas)
.60 calendar months
R01 CA 112358 (Liau)
04/01/06-06/30/11
NIH/NCI
$1,000,000
Dendritic cell-based vaccine targeting MAA in malignant gliomas.
Role: Co-Investigator
.24 calendar months
PENDING
P01 CA132681 (Baltimore)
NIH/NCI
Stem Cell Engineered Tumor Immunity in Man
Role: Principal Co-Investigator
04/01/08-03/30/12
$17,987,545
R01 NS054093 (Liau)
2007-2012
NIH/NCI
$1,125,000
Adoptive transfer of allo CTL for immunotherapy of recurrent grade III gliomas.
Role: Co-Investigator
PHS 398/2590 (Rev. 09/06)
Page _____
2.4 calendar months
.60 calendar months
Other Support Format Page